Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the investigators study is to compare the efficacy and safety of combining
trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant
therapy in Chinese HER2-positive breast cancer patients. 100 patients from multicenter would
be randomly assigned into two treatment arms and receive neoadjuvant chemotherapy followed by
operation and adjuvant treatment. The main end point of this study would be the efficacy and
safety of the two treatment arms, and the trend of the two curves is anticipated.